HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
<p>Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it comes to the prognostic properties the situation is different. Despite the fact that it is more than 20 years ago since...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ivyspring International Publisher
2012-01-01
|
| Series: | Journal of Cancer |
| Online Access: | http://www.jcancer.org/v03p0137.htm |
| _version_ | 1828498772781432832 |
|---|---|
| author | Jan Trøst Jørgensen, Maria Hersom |
| author_facet | Jan Trøst Jørgensen, Maria Hersom |
| author_sort | Jan Trøst Jørgensen, Maria Hersom |
| collection | DOAJ |
| description | <p>Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it comes to the prognostic properties the situation is different. Despite the fact that it is more than 20 years ago since the first studies demonstrating an association between a positive HER2 status and poor prognosis were published the issue is still controversial. In this current systematic review a large number of studies on HER2 and gastric cancer have been reviewed. The studies included in this review should fulfill the following two criteria. First criterion: The number of patients in each study should be ≥ 100, and the HER2 status should have been determined either by immunohistochemistry (IHC) or in situ hybridization (ISH). Second criterion: The selected articles should include an analysis of the association between the HER2 status and survival or relevant clinicopathological characteristics. Forty-two publications with a total of 12,749 patients fulfilled the two criteria and were reviewed in detail. The majority of the publications (71%) showed that a HER2-postive status measured either by IHC or ISH was associated with poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph node metastases, disease stage, or distant metastases. Based on the current analysis a clear trend towards a potential role for HER2 as a negative prognostics factor in gastric cancer was shown, suggesting that HER2 overexpression and/or amplification is a molecular abnormality that might be linked to the development of gastric cancer.</p> |
| first_indexed | 2024-12-11T13:12:07Z |
| format | Article |
| id | doaj.art-9ba892f85894453fbb2e6229c6c6225a |
| institution | Directory Open Access Journal |
| issn | 1837-9664 |
| language | English |
| last_indexed | 2024-12-11T13:12:07Z |
| publishDate | 2012-01-01 |
| publisher | Ivyspring International Publisher |
| record_format | Article |
| series | Journal of Cancer |
| spelling | doaj.art-9ba892f85894453fbb2e6229c6c6225a2022-12-22T01:06:09ZengIvyspring International PublisherJournal of Cancer1837-96642012-01-0131137144HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the LiteratureJan Trøst Jørgensen, Maria Hersom<p>Through the recent conduct of the ToGA trial, HER2 has shown to be predictive for the treatment with trastuzumab in advanced gastric and gastro-oesophageal cancer. When it comes to the prognostic properties the situation is different. Despite the fact that it is more than 20 years ago since the first studies demonstrating an association between a positive HER2 status and poor prognosis were published the issue is still controversial. In this current systematic review a large number of studies on HER2 and gastric cancer have been reviewed. The studies included in this review should fulfill the following two criteria. First criterion: The number of patients in each study should be ≥ 100, and the HER2 status should have been determined either by immunohistochemistry (IHC) or in situ hybridization (ISH). Second criterion: The selected articles should include an analysis of the association between the HER2 status and survival or relevant clinicopathological characteristics. Forty-two publications with a total of 12,749 patients fulfilled the two criteria and were reviewed in detail. The majority of the publications (71%) showed that a HER2-postive status measured either by IHC or ISH was associated with poor survival and/or clinicopathological characteristics, such as serosal invasion, lymph node metastases, disease stage, or distant metastases. Based on the current analysis a clear trend towards a potential role for HER2 as a negative prognostics factor in gastric cancer was shown, suggesting that HER2 overexpression and/or amplification is a molecular abnormality that might be linked to the development of gastric cancer.</p>http://www.jcancer.org/v03p0137.htm |
| spellingShingle | Jan Trøst Jørgensen, Maria Hersom HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature Journal of Cancer |
| title | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature |
| title_full | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature |
| title_fullStr | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature |
| title_full_unstemmed | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature |
| title_short | HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature |
| title_sort | her2 as a prognostic marker in gastric cancer a systematic analysis of data from the literature |
| url | http://www.jcancer.org/v03p0137.htm |
| work_keys_str_mv | AT jantr248stj248rgensenmariahersom her2asaprognosticmarkeringastriccancerasystematicanalysisofdatafromtheliterature |